YOUNGER patients are now eligible for Zostavax to prevent shingles

May 2011

YOUNGER patients are now eligible for Zostavax to prevent shingles.

Zostavax is now approved by FDA for ages 50 and up...instead of just 60 and up. This will likely be adopted soon by CDC.

This means about 40 million MORE people will be candidates...if you can get the vaccine. Zostavax is still in short supply because Merck is concentrating on making Varivax for chickenpox instead.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote